Zinc acetate treatment in Wilson's disease

Annals of Pharmacotherapy

Volumn 32, Issue 1, 1998, Pages 78-87

  Anderson, Leigh A ^a   Hakojarvi, Sara L ^b   Boudreaux, Stacey K ^b  

^a Multum Information Services Inc   (United States)

^b Multum Information Services Inc

Author keywords

Copper toxicosis; Wilson's disease; Zinc acetate

Indexed keywords

ALKALINE PHOSPHATASE; AMYLASE; CERULOPLASMIN; COPPER ION; GLUCONATE ZINC; IRON; METALLOTHIONEIN; PENICILLAMINE; TRIACYLGLYCEROL LIPASE; TRIENTINE; ZINC ACETATE; ZINC SULFATE;

CHELATION; CONTROLLED STUDY; COPPER METABOLISM; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATION; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; PYRIDOXINE DEFICIENCY; REVIEW; THROMBOCYTOPENIA; WILSON DISEASE;

AGE FACTORS; CLINICAL TRIALS; COPPER; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; LACTATION; PREGNANCY; ZINC ACETATE;

EID: 0031935374     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17075     Document Type: Review

References (57)

1. Hoogenraad TU, Van Hattum J, Van den Hamer CJA. Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients. J Neurol Sci 1987;77:137-46.
2. Milanino R, Marrella M, Moretti U, Velo GP, Deganello A, Ribezzo G, et al. Oral zinc sulfate as primary therapeutic intervention in a child with Wilson's disease. Eur J Pediatr 1989;148:654-5.
3. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine 1992;71: 139-64.
4. Package insert. Galzin (zinc acetate). Sellersville, PA: Teva Pharmaceuticals USA, December 1996.
5. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson's disease with zinc XIII: therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994; 123:849-58.
6. Yarze JC, Martin P, Muñoz SJ, Friedman LS. Wilson's disease: current status. Am J Med 1992;92:643-54.
7. Brewer GJ, Yuzbasiyan-Gurkan V, Dicks R, Wang Y, Johnson V. Does a vegetarian diet control Wilson's disease? J Am Coll Nutr 1993;12:527-30.
8. Brewer GJ. Practical recommendations and new therapies for Wilson's disease. Drugs 1995;50:240-9.
9. Stremmel W. Meyerrose K, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med 1991;115:720-6.
10. Czajka-Narins CM. Minerals. In: Mahan LK, Escott-Stump S, eds. Krause's food, nutrition, and diet therapy. 9th ed. Philadelphia: WB Saunders Co., 1996:148.
11. Scheinberg H. Wilson's disease. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AJ, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:2088-90.
12. Deiss A. Wilson's disease, In: Bennet JC, Plum F, eds. Cecil textbook of medicine. 20th ed. Philadelphia: WB Saunders Co., 1996:1131-2.
13. Akil M, Schwartz JA, Dutchak D, Yuzbasiyan-Gurkan V, Brewer GJ. The psychiatric presentations of Wilson's disease. J Neuropsychiatry Clin Neurosci 1991;3:377-82.
14. Schagen van Leewen JH, Christiaens GC, Hoogenraad TU. Recurrent abortion and the diagnosis of Wilson disease. Obstet Gynecol 1991;78: 547-9.
15. Brewer GJ, Hill GM, Prasad AS, Cosaack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983;99:314-20.
16. Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE. Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology 1987;7:522-8.
17. Friedman LS. Zinc in the treatment of Wilson's disease: how it works. Gastroenterology 1993;104:1566-8.
18. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992;120:380-6.
19. Rossaro L, Sturniolo GC, Giacon G, Montino MC, Lecis PE, Schade RR, et al. Zinc therapy in Wilson's disease: observations in five patients. Am J Gastroenterol 1990;85:665-8.
20. Brewer GJ, Yuzbasiyan-Gurkan V, Lee D, Appelman H. Treatment of Wilson's disease with zinc. VI. Initial treatment studies. J Lab Clin Med 1989;114:633-8.
21. Sandstead HH. Zinc treatment of Wilson's disease. J Lab Clin Med 1989;114:615-6.
22. Henderson LM, Brewer GJ, Dressman JB, Swiden SZ, DuRoss DJ, Adair CH, et al. Effect of intragastric pH on the absorption of oral zinc acetate and zinc oxide in young healthy volunteers. JPEN J Parenter Enteral Nutr 1995;19:393-7.
23. Pecoud A, Donzel P, Schelling JL. Effects of foodstuffs on the absorption of zinc sulfate. Clin Pharmacol Ther 1975;17:469-74.
24. Brewer GJ, Yuzbasiyan-Gurkan V, Lee D. Use of zinc-copper metabolic interactions in the treatment of Wilson's disease. J Am Coll Nutr 1990;9:487-91.
25. Lee HH, Prasad AS, Brewer GJ, Owyang C. Zinc absorption in human small intestine. Am J Physiol 1989;256:G87-91.
26. Lipsky MA, Gollan JL. Treatment of Wilson's disease: In d-penicillamine we trust - what about zinc? Hepatology 1987;7:593-5.
27. Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, Wells JJ, et al. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med 1987;109:526-31.
28. Veen C, Van den Hamer CJA, De Leeuw PW. Zinc sulfate therapy for Wilson's disease after acute deterioration during treatment with low-dose d-penicillamine. J Int Med 1991;229:549-52.
29. Hoogenraad TU, Van den Hamer CJA, Hattum JV. Effective treatment of Wilson's disease with oral zinc sulfate: two case reports. Br Med J 1984;289:273-6.
30. Mayet IY. Low-dose zinc therapy for maintenance treatment of Wilson's disease. Clin Pharm 1990;9:951-3.
31. Hoogenraad TU, Van den Hamer CJA. 3 Years of continuous oral zinc therapy in 4 patients with Wilson's disease. Acta Neurol Scand 1983,67: 356-64.
32. Walshe JM. Treatment of Wilson's disease with zinc sulfate. Br Med J 1984;289:558-9.
33. Moore R. Bleeding gastric erosion after oral zinc sulfate. Br Med J 1978;1:754.
34. Milanino R, Deganello A, Marrella M, Michielutti F, Moretti U, Pasqualicchio M, et al. Oral zinc therapy as initial therapy in Wilson's disease: two years of continuous treatment in a 10-year old child. Acta Paediatr 1992;81:163-6.
35. Van Caillie-Bertrand M, Degenhart HJ, Visser HKA, Sinaasappel M, Bouquet J. Oral zinc sulfate for Wilson's disease. Arch Dis Child 1985; 60:656-9.
36. Brewer GJ, Yuzbasiyan-Gurkan V, Young AB. Treatment of Wilson's disease. Semin Neurol 1987;7:209-20.
37. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982;1:643-7.
38. Deiss A. Treatment of Wilson's disease. Ann Intern Med 1983;99:398-400.
39. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48:42-7.
40. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. Treatment of Wilson's disease with zinc IX: response of serum lipids. J Lab Clin Med 1991; 118:466-70.
41. Yuzbasiyan-Gurkan V, Brewer GJ, Abrams GD, Main B, Giacherio D. Treatment of Wilson's disease with zinc. V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson's disease. J Lab Clin Med 1989;114:520-6.
42. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA 1984;252:1443-6.
43. Yamaguchi M, Takahashi K, Okada S. Zinc-induced hypocalcemia and bone resorption in rats. Toxicol Appl Pharmacol 1983;67:224-8.
44. Shimon I, Sela B, Moses B, Dolev E. Hemolytic episode in a patient with Wilson's disease treated with zinc. Isr J Med Sci 1993;29:646-7.
45. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anti-copper agents. J Am Coll Nutr 1993;12:26-30.
46. Hansten PD, Horn JR, eds. Drug interactions and updates. Volume 16. Vancouver, WA: Applied Therapeutics, Inc., 1996:261,281.
47. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams and Wilkins, 1994:xx.
48. Physicians' desk reference. 51st ed. Montvale, NJ: Medical Economics Company, 1997:1674,1791.
49. Goldenberg RL, Tamura T, Neggers Y, Copper RL, Johnston KE, Du-Bard MB, et al. The effect of zinc supplementation on pregnancy outcome. JAMA 1995;274:463-8.
50. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc XII: dose regimen requirements. Am J Med Sci 1993;305:199-202.
51. Brewer GJ, Yuzbasiyan-Gurkan V, Dick RD. Zinc therapy of Wilson's disease VIII: dose response studies. J Trace Elem Exp Med 1990;3:227-34.
52. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson's disease with ammonium tetrathiomolybdate II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996;53:1017-25.
53. Siegemund R, Lobner J, Gunther K, Kuhn HJ, Bachmann H. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease. Acta Neurol Scand 1991;83:364-6.
54. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987;44:490-3.
55. The Pink Sheet. Teva's Galzin Phase IV Wilson's disease studies to include pediatric dosing, monitoring of pregnant women; zinc acetate will be available by end of March. FDC Reports 1997;February 3:11-2.
56. 1996 Drug topics red book. Montvale, NJ: Medical Economics, 1996: 202,465,762-3.
57. Walshe JM, Dixon AK. Dangers of noncompliance in Wilson's disease. Lancet 1986;1:845-7.